It is intended to provide an anti-tumor agent for sex hormone sensitive cancer. According to the invention, it was demonstrated that hydroxycitric acid (HCA) inhibits the growth of a sex hormone sensitive cancer cell. In the past, HCA was demonstrated to be safer than citric acid in acute toxicity studies and the anti-tumor agent of the invention containing HCA as an active ingredient is expected to have less side effects than conventionally known anti-tumor agents. Further, the pharmaceutical composition containing HCA is considered to be useful for the treatment of not only cancer but also other diseases caused by the proliferation of a sex hormone sensitive cell.
展开▼
